Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on May 25, 2018. The report discloses the appointment of Brian P. McVeigh as Chief Business Officer (CBO), effective May 29, 2018. The company is incorporated in Delaware and maintains its principal executive offices in Boston, Massachusetts.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- Base Salary: $400,000 annually.
- Target Bonus: 40% of annual base salary.
- Equity Grant: Option to purchase 225,000 shares of common stock.
- Equity Vesting: 25% on the first anniversary; the remainder vests in equal monthly installments over the subsequent three years.
Material Changes
The primary material change is the addition of a new senior executive to the management team. Brian P. McVeigh joins from KBP Biosciences, where he served as CEO and Board member until April 2018. Prior to that, he held various senior business development and M&A roles at GlaxoSmithKline plc from 1992 to 2017.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or operational outlook. However, it details specific contractual risks and contingencies regarding the new executive's employment:
- Severance (Termination without Cause/Good Reason): Eligible for 9 months of base salary continuation and 9 months of subsidized COBRA medical benefits.
- Change in Control: If terminated without cause or for good reason within 12 months of a change in control, the executive receives 12 months of base salary, 12 months of COBRA benefits, and immediate acceleration of all stock options.
- Definitions: The agreement strictly defines "cause" (e.g., felony, fraud, gross negligence) and "good reason" (e.g., material diminution of title or salary, relocation of 50+ miles).
Investor Verification Checklist
- Verify the company name is Zafgen, Inc., as the metadata reference to Larimar Therapeutics appears to be incorrect.
- Review the attached Exhibits 10.1 (Employment Offer Letter) and 10.2 (Severance Agreement) for full legal terms.
- Confirm the impact of the 225,000 share option grant on existing shareholder dilution.
- Monitor the company's cash position to ensure it can support the new executive's compensation and potential severance obligations.